Using modified immune cells to treat lung cancer
Flt3l gene-modified cDC1 in situ vaccination in NSCLC: mechanisms and therapeutic application
This study is exploring a new way to boost the immune system's fight against non-small cell lung cancer by using specially modified cells to help activate T cells right in the tumor, and it could offer new hope for patients looking for better treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10863820 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune response against non-small cell lung cancer (NSCLC) by modifying dendritic cells to improve their ability to stimulate T cells. The approach involves using gene-modified cells to create a localized vaccination effect within the tumor environment. Patients may benefit from this innovative immunotherapy that aims to activate their immune system to better fight cancer. The research is being conducted by a team of experts in lung cancer and immunology, ensuring a robust methodology and support.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer who are seeking new treatment options.
Not a fit: Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
Los Angeles, United States
- VA Greater Los Angeles Healthcare System — Los Angeles, United States (Active)
Researchers
- Principal investigator: Salehi-Rad, Ramin — VA Greater Los Angeles Healthcare System
- Study coordinator: Salehi-Rad, Ramin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.